Company expands strategic focus into one of oncology’s most urgent supportive-care challenges Jericho, New York, April 02, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) ...
Sept. 14 (UPI) --A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical tests, drugmaker Pfizer announced Saturday. The experimental ...
Until recently, the root cause of cachexia was identified as the inflammatory mediators produced either by the tumour itself ...
It has been known for many years that advanced cancer is associated with a wasting syndrome that speeds the demise of patients. About one-quarter to a third of patients with advanced cancer develop ...
The investigational drug ponsegromab — which inhibits growth differentiation factor 15 (GDF-15), a cytokine elevated in cancer cachexia — increases weight, appetite, and physical activity in patients ...
Cachexia in older SCLC patients leads to inferior survival rates and increased treatment complications, such as dose reductions and incomplete chemotherapy courses. Patients with cachexia had ...
Opportunities in the market include increasing demand for personalized treatments, advancements in muscle preservation ...
Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. Seventy patients with an Eastern Cooperative Oncology ...
In 2011, Laura Beaver did not let the growing tumor in her body dictate her life. She kept up her normal hourlong gym routine. She took weekend bike rides near her Washington state home. She did the ...
Eating disorders are often thought of as body image disorders with symptoms of food restriction and purging. In most cases, the goal of these behaviors is to prevent weight gain. Not all eating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results